Protocols›Metabolic, weight & GH›Body Composition
← Protocols
Athlete / performance · uptakeCommunity · convergenceNo approved clinical use

Body Composition

Stack: AOD-9604 + Ipamorelin + CJC-1295 · recomposition support
"A recomposition stack built on a fat-loss fragment whose own human trials were largely negative. Popular intent, weak underlying evidence."
GoalRecomposition support
Compounds3 · AOD-9604 + Ipamorelin + CJC-1295
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): not approved · AOD-9604 human trials largely negative
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Athlete / performance
Where / who
Community / athlete and clinic use as tagged above.
Use status
Common recomp community stack.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
AOD-9604 / Ipamorelin / CJC-1295: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. AOD-9604 human data largely negative.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

AOD-9604 anchors the fat-loss claim — but its human obesity trials were largely negative. The GH-axis pair adds biomarker effect. The combination's recomposition claim is weakly supported.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription. Specific timing is part of membership.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

Common recomp community stack.

Human efficacy Weak

AOD-9604 human data largely negative.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Weak foundation under a popular goal.

Fast facts
Compounds

AOD-9604 · Ipamorelin · CJC-1295

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material